Bristol-Myers Squibb's (BMY) Opdivo for Treatment of Esophageal Cancer Granted Orphan Drug Status by FDA
- Wall St. opens higher as M&A activity boosts confidence
- AT&T (T) to Acquire Time Warner (TWX) for $107.50/Share
- Rockwell Collins (COL) to Acquire B/E Aerospace (BEAV) for $6.4B
- TD Ameritrade (AMTD) to Acquire Scottrade in $4B Cash & Stock Deal
- Pre-Open Stock Movers 10/24: (BEAV) (JPEP) (HLT) Higher; (BAS) (INO) (ADRO) Lower (more...)
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Bristol-Myers Squibb's (NYSE: BMY) Opdivo for treatment of esophageal cancer was granted orphan drug status by the FDA. The generic name is nivolumab.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb (BMY) Announces FDA Acceptance of Opdivo sBLA as Treatment for Adv. Bladder Cancer
- ChromaDex (CDXC) Announces Publication of Data on NAD+ Precursors NR, NMN
- Bristol-Myers Squibb’s Coast 2 Coast 4 Cancer Ride Raises Over $1 Million for Cancer Research
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!